Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 10Rituximab 9polatuzumab vedotin 6Prednisone 6Doxorubicin 6Vincristine 5zanubrutinib 4glofitamab 4Prednisolone 4Lenalidomide 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Lisaftoclax 3tafasitamab 2obinutuzumab 2fludarabine 2Radiotherapy 2R-CHOP protocol 2Observation 2venetoclax 1sintilimab 1resiniferatoxin 1penpulimab 1pegfilgrastim 1orelabrutinib 1loncastuximab tesirine 1duvelisib 1acalabrutinib 1Vancomycin 1Therapeutics 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Large B-Cell, Diffuse × Homoharringtonine × Clear all
NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Affiliated Hospital of Zhejiang University

Phase 1/2 Not yet recruiting
62 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡